Two months after Merck & Co. and Roche inked a deal to promote Merck's Victrilis (boceprevir) in the U.S. as part of a triple combination therapy for chronic hepatitis C (HCV), the companies are
expanding their marketing effort overseas. Merck says it will work with Roche in Europe, Asia, and Latin America to educate physicians and patients about HCV and promote Victrelis in combination with
peginterferon alfa and ribavirin (peg/riba).
Read the whole story at Genetic Engineering And Biotechnology News »